All In Biotech

Drug Trial Radar · NCT07455955

Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile

Phase II Study of Personalized Antiemetic Regimen Based on Pharmacogenetic Profile for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients.

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 31, 2026

Primary completion

Jun 3, 2027

Study completion Jul 3, 2028

Sponsor

Lead sponsor
Chinese University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study are to determine if pharmacogenetic (PG) analysis of an individual enable optimal selection of antiemetic regimen for patients undergoing the first cycle of AC (Adriamycin + Cyclophosphamide) or FEC (Fluorouracil + Epirubicin + Cyclophosphamide) chemotherapy. It also aims to compare the quality of life of patients in the first cycle of AC / FEC chemotherapy with PG analysis. Patients enrolled into this study will be named as "Upfront-PG patients". Outcomes of the Upfront-PG patients in this prospective study will be compared to a historical control group (i.e. the "Non-upfront-PG patients"). The historical control group comprised of patients who were enrolled into a prior study. The latter did not have upfront PG analysis. These Non-upfront-PG patients received Standard antiemetic regimen, with PG analysis performed retrospectively as part of that prior study.

Conditions

  • Breast Cancer

Interventions

  • Standard antiemetic regimen or Olanzapine antiemetic regimenDrug

    Standard antiemetic regimen: * Day 1: Aprepitant 125mg QD (once daily); Ondansetron 8mg BD (twice daily); Dexamethasone 12mg QD (Aprepitant, Ondansetron and Dexamethasone to be take 60 minutes before chemotherapy on Day 1) * Days 2 to 3: Aprepitant 80mg QD Olanzapine antiemetic regimen: * Day 1: Aprepitant 125mg QD; Ondansetron 8mg BD; Dexamethasone 12 mg QD; Olanzapine 10mg QD (Aprepitant, Ondansetron and Dexamethasone to be take 60 minutes before chemotherapy on Day 1); Olanzapine 10mg nocte * Days 2 to 3: Aprepitant 80mg QD; Olanzapine 10mg nocte * Days 4-5: Olanzapine 10mg nocte

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Protection (CP)Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Clinical Oncology, Prince of Wales Hospital

    Hong Kong, Hong Kong · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.